Canonical: https://ownershiptrace.com/13f/companies/855

# Who owns ALNYLAM PHARMACEUTICALS, INC. (ALNY)? Elite investor 13F holders

5 tracked elite investors reported holding ALNYLAM PHARMACEUTICALS, INC as of 2026-06-30, including Dodge & Cox Funds, D.E. Shaw, Bridgewater Associates, Gotham Asset Management, Ancora Advisors / Ancora Holdings. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

5 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute…

## Reported holders and securities, including exits (up to 20)

| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|  --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| [Dodge & Cox Funds](https://ownershiptrace.com/13f/investors/29) | ALNYLAM PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 588631955.00 USD | 1955393.000000 | Shares | add | [Original filing](https://www.sec.gov/Archives/edgar/data/200217/0001193125-26-349535-index.html) |
| [D.E. Shaw](https://ownershiptrace.com/13f/investors/98) | ALNYLAM PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 332369932.00 USD | 1104109.000000 | Shares | add | [Original filing](https://www.sec.gov/Archives/edgar/data/1009207/0001104659-26-097217-index.html) |
| [Bridgewater Associates](https://ownershiptrace.com/13f/investors/8) | ALNYLAM PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 29977772.00 USD | 99584.000000 | Shares | reduce | [Original filing](https://www.sec.gov/Archives/edgar/data/1350694/0001350694-26-000003-index.html) |
| [Gotham Asset Management](https://ownershiptrace.com/13f/investors/94672) | ALNYLAM PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 12658613.00 USD | 42051.000000 | Shares | reduce | [Original filing](https://www.sec.gov/Archives/edgar/data/1510387/0001398344-26-014644-index.html) |
| [Ancora Advisors / Ancora Holdings](https://ownershiptrace.com/13f/investors/101) | ALNYLAM PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 3311.00 USD | 11.000000 | Shares | hold | [Original filing](https://www.sec.gov/Archives/edgar/data/1446114/0001446114-26-000012-index.html) |

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

[How to read the data](https://ownershiptrace.com/docs#reading-the-data) · [Disclaimer](https://ownershiptrace.com/disclaimer)